help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, J. C.
Right arrow Articles by Davies, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, J. C.
Right arrow Articles by Davies, J. S.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 6 2556-2561
Copyright © 2003 by The Endocrine Society

The Effects of Depot Long-Acting Somatostatin Analog on Central Aortic Pressure and Arterial Stiffness in Acromegaly

J. C. Smith, H. Lane, N. Davies, L. M. Evans, J. Cockcroft, M. F. Scanlon and J. S. Davies

Departments of Medicine (J.C.S., H.L., N.D., L.M.E., M.F.S., J.S.D.) and Cardiology (J.C.), University Hospital of Wales, Cardiff, CF4 4XN, Wales, United Kingdom

Address all correspondence and requests for reprints to: Dr. Jamie C. Smith, Department of Diabetes and Endocrinology, Old Building, Bristol Royal Infirmary, Bristol, BS2 8HW, United Kingdom. E-mail: jamie.smith{at}virgin.net.

Acromegaly is associated with increased cardiovascular risk. Although conventional risk factors such as glucose intolerance, hypertension, and dyslipidemia probably contribute, there may also be direct effects of GH/IGF-I excess on the vasculature. To study the effects of GH excess on the vasculature, we have assessed arterial stiffness in acromegalic subjects with and without active disease and have investigated the effects of Sandostatin LAR (OCT-LAR) on vascular function.

Sixteen normotensive subjects with acromegaly (10 males and 6 females) and 8 healthy controls were studied. Of the acromegalic subjects, eight had active disease (group A), and eight were cured (GH < 2.5 mU/liter; group B). The three groups were age, sex, and blood pressure matched. Group A subjects were restudied after 3 and 6 months of OCT-LAR therapy. Arterial stiffness was assessed by analyzing central arterial pressure waveforms derived from measured radial artery waveforms. This allowed determination of the augmentation of central pressure and the augmentation index. Lipids, glucose, and IGF-I were also measured.

Comparing the three groups (ANOVA; mean ± SD), the augmentation index was higher in group A (28 ± 12 vs. 12 ± 13%; P < 0.01) but not in group B (22 ± 7 vs. 12 ± 13%; P = 0.60), compared with controls. IGF-I was higher in group A (50.3 ± 21.2 nmol/liter; P < 0.01), compared with group B (22.5 ± 8.9 nmol/liter) and controls (19.5 ± 5.3 nmol/liter). On regression analysis, IGF-I concentration was identified as a strong independent predictor of the augmentation index (ß = 0.50; P = 0.007). There were no significant differences in aortic systolic pressure, aortic diastolic pressure, lipids, or glucose. Compared with baseline, OCT-LAR treatment resulted in a lowering of augmentation index at 3 months (20 ± 15 vs. 28 ± 12%; P < 0.05), but at 6 months (24 ± 16%; P = 0.21) there was no significant change. IGF-I was reduced from 50.3 ± 21.2 nmol/liter at baseline to 31.4 ± 13.2 nmol/liter at 3 months (P < 0.05) and 26.6 ± 15.8 nmol/liter at 6 months (P < 0.05).

In conclusion, acromegaly is associated with changes in the central arterial pressure waveform, suggesting large artery stiffening. This may have important implications for cardiac morphology and performance in acromegaly as well as increasing the susceptibility to atheromatous disease. Large artery stiffness is reduced in cured acromegaly and partially reversed after pharmacological treatment of active disease.

J.C. is supported by the British Heart Foundation.

Abbreviations: HDL, High-density lipoprotein; LDL, low-density lipoprotein; NO, nitric oxide.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
J. J. Puder, S. Nilavar, K. D. Post, and P. U. Freda
Relationship between Disease-Related Morbidity and Biochemical Markers of Activity in Patients with Acromegaly
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1972 - 1978.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society